Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed
Mark S. Butler(The University of Queensland), Peter Beyer, Guy Thwaites(University of Oxford), Sarah Paulin, Lloyd G. Czaplewski(University of Kent), Laila Al-Sulaiman, César A. Arias(Universidad El Bosque), Melvin Spigelman(TB Alliance), Roman S. Kozlov(Smolensk State Medical University), Valeria Gigante(World Health Organization), Stephan Harbarth(University Hospital of Geneva), John Rex(AstraZeneca (Brazil)), Christian Lienhardt(Institut de Recherche pour le Développement), Richard A. Alm(AstraZeneca (United States)), Norio Ohmagari(National Center for Global Health and Medicine), Mical Paul(Rabin Medical Center), Prabhavathi Fernandes(Global Antibiotic Research & Development Partnership), Lynn L. Silver, Hatim Sati(World Health Organization)
Archive ouverte UNIGE (University of Geneva)
January 1, 2022
Cited by 221
Related Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
|Clinical Infectious Diseases|2002|2.3k
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Guidelines for Treatment of Candidiasis
|Clinical Infectious Diseases|2004|1.4k
Practice Guidelines for the Treatment of Candidiasis
|Clinical Infectious Diseases|2000|927